Loading clinical trials...
Loading clinical trials...
Clinical Study on the Safety, Efficacy, and Pharmacokinetics of a Universal CD19-Targeted CAR-T Cell Injection (RD06-04) in the Treatment of Patients With Refractory Inflammatory Myopathy and ANCA-Associated Vasculitis
Conditions
Interventions
RD06-04 Cell Injection Infusion
Locations
1
China
Peking University People's Hospital
Beijing, China
Start Date
June 14, 2025
Primary Completion Date
December 31, 2025
Completion Date
December 31, 2026
Last Updated
May 22, 2025
NCT07295847
NCT07361094
NCT06479863
NCT07089121
NCT06991114
NCT07151521
Lead Sponsor
Peking University People's Hospital
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions